CY1706A - Thiazepine compounds - Google Patents

Thiazepine compounds

Info

Publication number
CY1706A
CY1706A CY170694A CY170694A CY1706A CY 1706 A CY1706 A CY 1706A CY 170694 A CY170694 A CY 170694A CY 170694 A CY170694 A CY 170694A CY 1706 A CY1706 A CY 1706A
Authority
CY
Cyprus
Prior art keywords
thiazepine compounds
thiazepine
compounds
Prior art date
Application number
CY170694A
Other languages
English (en)
Original Assignee
Ici America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10595359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1706(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ici America Inc filed Critical Ici America Inc
Publication of CY1706A publication Critical patent/CY1706A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY170694A 1986-03-27 1994-01-14 Thiazepine compounds CY1706A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868607684A GB8607684D0 (en) 1986-03-27 1986-03-27 Thiazepine compounds

Publications (1)

Publication Number Publication Date
CY1706A true CY1706A (en) 1994-01-14

Family

ID=10595359

Family Applications (2)

Application Number Title Priority Date Filing Date
CY170694A CY1706A (en) 1986-03-27 1994-01-14 Thiazepine compounds
CY1998045C CY98045I2 (el) 1986-03-27 1998-10-30 Thiazepine compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY1998045C CY98045I2 (el) 1986-03-27 1998-10-30 Thiazepine compounds

Country Status (31)

Country Link
US (1) US4879288A (fr)
EP (1) EP0240228B1 (fr)
JP (1) JPH064606B2 (fr)
KR (1) KR900001868B1 (fr)
AR (1) AR242198A1 (fr)
AT (1) ATE58132T1 (fr)
AU (1) AU593336B2 (fr)
BG (1) BG61365B2 (fr)
CA (1) CA1288428C (fr)
CY (2) CY1706A (fr)
DD (1) DD259403A5 (fr)
DE (3) DE10075016I2 (fr)
DK (1) DK174618B1 (fr)
ES (1) ES2019379T4 (fr)
FI (1) FI86059C (fr)
GB (2) GB8607684D0 (fr)
GR (1) GR3001061T3 (fr)
HK (1) HK85393A (fr)
HU (1) HU201062B (fr)
IE (1) IE59864B1 (fr)
IL (1) IL81923A (fr)
LU (1) LU90593I2 (fr)
MW (1) MW2087A1 (fr)
NL (1) NL980022I2 (fr)
NO (2) NO168771C (fr)
NZ (1) NZ219788A (fr)
PH (1) PH26516A (fr)
PT (1) PT84569B (fr)
ZA (1) ZA871940B (fr)
ZM (1) ZM2987A1 (fr)
ZW (1) ZW5787A1 (fr)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
DE3827447A1 (de) * 1988-08-12 1990-04-26 Basf Ag Polyazofarbstoffe und deren zwischenprodukte
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
GB9109557D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5240927A (en) * 1992-05-19 1993-08-31 Hoechst-Roussel Pharmaceuticals Incorporated Benzo[β]thiophen-3-yl piperazines as antipsychotic agents
WO1997035584A1 (fr) * 1996-03-25 1997-10-02 Eli Lilly And Company Procede de traitement de la douleur
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
GB9716161D0 (en) * 1997-08-01 1997-10-08 Zeneca Ltd Process
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0003126D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
DE60125062T2 (de) * 2000-12-20 2007-05-31 Astrazeneca Ab Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten
EP1795199A3 (fr) * 2001-02-06 2007-07-25 AstraZeneca AB Quétiapine pour traiter la dépendance à une substance ou l'abus d'une substance
ATE360425T1 (de) 2001-02-06 2007-05-15 Astrazeneca Ab Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
SI1458888T1 (sl) * 2001-12-10 2011-07-29 Novartis Ag Metode zdravljenja psihoze in shizofrenije na osnovi polimorfizmov gena cntf
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
AU2003235435A1 (en) * 2002-03-20 2003-10-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
KR100707050B1 (ko) 2002-11-28 2007-04-13 에스케이 주식회사 10Ｈ-디벤조[ｂ,ｆ][1,4]티아제핀-11-온의 제조방법
MXPA05007016A (es) * 2003-01-14 2005-09-12 Gilead Sciences Inc Composiciones y metodos para terapia antiviral de combinacion.
EP1495008A1 (fr) * 2003-02-22 2005-01-12 Teva Pharmaceutical Industries Limited Synthese de la quetiapine et sels acceptables d'un point de vue pharmaceutique de celle-ci
TR200503401T1 (tr) * 2003-03-03 2008-03-21 Hetero Drugs Limited Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
US7053115B2 (en) * 2003-04-07 2006-05-30 Hetero Drugs Limited Crystalline form of dorzolamide hydrochloride
WO2004100992A2 (fr) * 2003-05-16 2004-11-25 Pfizer Products Inc. Combinaisons therapeutiques d'antipsychotiques atypiques avec des modulateurs de l'acide 4-aminobutanoique et/ou des medicaments anticonvulsivants
US20070117789A1 (en) * 2005-11-18 2007-05-24 Astrazeneca Ab Method of treatment
US20060217365A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating mood disorders
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
US20090093460A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Compositions
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US20060229292A1 (en) * 2005-01-07 2006-10-12 Astrazeneca Ab Method of treating childhood disorders
US20060252743A1 (en) * 2005-01-07 2006-11-09 Astrazeneca Ab Method of treating sleep disorders
ES2349091T3 (es) * 2003-07-02 2010-12-27 Astrazeneca Ab Metabolito de quetiapina.
US20060217367A1 (en) * 2004-07-01 2006-09-28 Astrazeneca Ab Method of treating anxiety disorders
ES2223294B2 (es) * 2003-08-08 2005-10-01 Vita Cientifica, S.L. Procedimiento de preparacion de un compuesto farmaceuticamente activo.
US20050080072A1 (en) * 2003-09-01 2005-04-14 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of a thiazepine derivative
CA2538866A1 (fr) 2003-09-23 2005-03-31 Fermion Oy Procede de preparation de quetiapine
US20050158383A1 (en) * 2003-10-21 2005-07-21 Garth Boehm Quetiapine formulations
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
SG133606A1 (en) 2003-12-22 2007-07-30 Acadia Pharm Inc Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
WO2005102366A2 (fr) * 2004-04-19 2005-11-03 Philip Maxwell Satow Combinaisons de lithium et utilisations associees
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
KR101038389B1 (ko) * 2004-06-23 2011-06-01 에스케이바이오팜 주식회사 11-(4-[2-(2-히드록시에톡시)에틸]-1-피페라지닐)-디벤조[ｂ,ｆ][1,4]티아제핀의 제조방법
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
ES2310366T3 (es) * 2004-08-24 2009-01-01 Janssen Pharmaceutica Nv Nuevos derivados de heteroaril sulfonamida benzo-condensada utiles como agentes anticonvulsivos.
WO2006027789A1 (fr) * 2004-09-08 2006-03-16 Jubilant Organosys Limited Procede de production de 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo[b,f][1,4]thiazepine et d'un sel acceptable sur le plan pharmaceutique associe
US20060063927A1 (en) * 2004-09-22 2006-03-23 Olga Etlin Processes for preparing quetiapine and salts thereof
WO2006035293A1 (fr) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Formes polymorphiques d'hemifumarate de quetiapine
WO2006056772A2 (fr) * 2004-11-23 2006-06-01 Pliva Hrvatska D.O.O. Composes pharmaceutiques
WO2006073360A1 (fr) * 2005-01-07 2006-07-13 Astrazeneca Ab Nouvelle utilisation de 11-piperazine-1-yldibenzo [b,f] [1,4] thiazepine ou de son sel pharmaceutiquement acceptable et compositions pharmaceutiques orales
EP1841751A1 (fr) * 2005-01-24 2007-10-10 IPCA Laboratories Limited SYNTHÈSE INDUSTRIELLE DE LA 11-[4- (2-(2-HYDROXYÉTHOXY)ÉTHYL)-1-PIPÉRAZINYL]DIBENZO[b,f]-1[1, 4]THIAZÉPINE
KR20070102563A (ko) * 2005-01-26 2007-10-18 엘란 파마 인터내셔널 리미티드 정신병치료제를 함유하는 조절방출형 조성물
ES2234447B1 (es) 2005-03-07 2006-03-01 Union Quimico-Farmaceutica S.A. Procedimiento para la obtencion de un derivado de 11-(4-sustituido-1-piperazinil)dibenzo(b,f)(1,4)tiazepina.
EP1863485A2 (fr) * 2005-03-18 2007-12-12 Abbott Laboratories Ligand du recepteur nicotinique neuronal alpha7 et compositions antipsychotiques
US7488821B2 (en) * 2005-04-04 2009-02-10 Divi's Laboratories Limited Polymorph of Quetiapine fumarate and a process for its preparation
JP2008502707A (ja) * 2005-04-14 2008-01-31 テバ ファーマシューティカル インダストリーズ リミティド クエチアピンフマレートの調製方法
US8048876B2 (en) 2005-04-21 2011-11-01 Medichem S.A. Process for preparing quetiapine and quetiapine fumarate
AR056321A1 (es) * 2005-04-22 2007-10-03 Wyeth Corp COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
JP2008545650A (ja) * 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US20070072840A1 (en) * 2005-05-30 2007-03-29 Pandya Bhargav Polymorphic forms of quetiapine
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
WO2007004234A1 (fr) * 2005-07-04 2007-01-11 Usv Limited PROCÉDÉ DE PRÉPARATION DU FUMARATE DE 2-[2-(4-DIBENZO[b,f][L,4]THIAZÉPIN-11-YL-1-PIPÉRAZINYL)ÉTHOXY]ÉTHANOL
GB0516603D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Processes for the preparation of organic compounds useful as serotonin receptor antagonists
WO2007036599A1 (fr) 2005-09-30 2007-04-05 Fermion Oy Nouveau procede de cristallisation d'hemifumarate de quetiapine
WO2007056457A2 (fr) 2005-11-09 2007-05-18 Combinatorx, Incorporated Procedes, compositions et kits pour le traitement de pathologies
WO2009151392A1 (fr) * 2008-06-14 2009-12-17 Astrazeneca Ab Nouveaux dérivés de 11-pipérazine-1-yldibenzo [b,f] [1,4] thiazépine pour traiter au moins un syndrome ou un état associé à la schizophrénie ou autres troubles psychotiques
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
US8389510B2 (en) * 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
WO2009151393A1 (fr) * 2008-06-14 2009-12-17 Astrazeneca Ab Nouveaux dérivés de la 11-pipérazin-l-yldibenzo[b,f][l,4]thiazépine pour traiter au moins un syndrome ou un état associé à la schizophrénie et autres troubles psychotiques
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20100178333A1 (en) * 2006-01-25 2010-07-15 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
WO2007102074A2 (fr) * 2006-03-07 2007-09-13 Cadila Healthcare Limited Sels de quetiapine
EP2026790A2 (fr) * 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Thérapie combinée pour le traitement de l'épilepsie et de troubles apparentés
ATE523602T1 (de) 2006-06-12 2011-09-15 Hadasit Med Res Service Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
CZ300451B6 (cs) * 2006-07-03 2009-05-20 Farmak, A. S. Zpusob prípravy solí 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanolu (quetiapinu) a jejich cištení
WO2008047340A1 (fr) * 2006-10-19 2008-04-24 Mor Research Applications Ltd. Thérapies combinées d'antipsychotiques et de tétracyclines dans le traitement de troubles psychiatriques
WO2008066620A2 (fr) * 2006-10-20 2008-06-05 Concert Pharmaceuticals Inc. Dérivés de dibenzodiazépine
WO2008052354A1 (fr) * 2006-11-03 2008-05-08 University Of Saskatchewan Méthode de traitement de maladies démyélinisantes
PT103884A (pt) 2006-11-17 2008-05-19 Astrazeneca Ab Composições de libertação prolongada e métodos para a sua preparação
ES2610508T3 (es) 2006-11-22 2017-04-27 Clinical Research Associates, Llc Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
CN101616585A (zh) * 2006-12-20 2009-12-30 阿斯利康(瑞典)有限公司 化合物及其用途
JP2010531292A (ja) * 2006-12-20 2010-09-24 アストラゼネカ・アクチエボラーグ 化合物及びその使用
EP2131817A2 (fr) 2007-03-09 2009-12-16 Synthon B.V. Composition pharmaceutique de fumarate de quétiapine
CN100569761C (zh) * 2007-04-18 2009-12-16 湖南洞庭药业股份有限公司 制备药物纯富马酸喹硫平的生产方法
US8101597B2 (en) * 2007-05-07 2012-01-24 Actavis Group Ptc Ehf Quetiapine salts and their polymorphs
HU230144B1 (hu) * 2007-06-12 2015-09-28 Richter Gedeon Nyrt. Eljárás quetiapin előállítására
US20090082334A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched quetiapine
US20090220593A1 (en) * 2008-01-29 2009-09-03 Gulati Inder Extended release dosage forms of quetiapine
JP2011510960A (ja) * 2008-01-31 2011-04-07 フェルミオン オサケ ユキチュア ケチアピンの製造方法
WO2009104080A2 (fr) 2008-02-20 2009-08-27 Targia Pharmaceuticals Compositions pharmaceutiques actives sur le snc et méthodes d'utilisation
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090264408A1 (en) * 2008-04-17 2009-10-22 Gulati Inder Extended release dosage forms of quetiapine
WO2009128058A1 (fr) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Produits psycho-pharmaceutiques
MX2010014203A (es) 2008-06-20 2011-02-22 Astrazeneca Ab Derivados de dibenzotiazepina y sus usos - 424.
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
WO2009156889A1 (fr) * 2008-06-25 2009-12-30 Pfizer Inc. Composés diaryle et leurs utilisations
AU2009265099A1 (en) * 2008-07-01 2010-01-07 Lupin Limited Sustained release pharmaceutical compositions comprising Quetiapine
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8173637B2 (en) * 2008-07-24 2012-05-08 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
EP2262486B1 (fr) * 2008-08-01 2013-01-02 KRKA, Tovarna Zdravil, D.D., Novo Mesto Composition de quétiapine
EP2153834A3 (fr) 2008-08-07 2010-02-24 Farmaprojects, S.A. Compositions pharmaceutiques à libération prolongée comportant des sels de quétiapine
DE102008046650A1 (de) * 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
WO2010031054A1 (fr) 2008-09-15 2010-03-18 Biovista, Inc. Compositions et procédés pour traiter l’épilepsie
WO2010082220A2 (fr) * 2009-01-05 2010-07-22 Torrent Pharmaceuticals Limited Composition pharmaceutique à libération prolongée à base de quétiapine et son procédé de préparation
WO2010089259A2 (fr) 2009-02-04 2010-08-12 Woerwag R&D Gmbh Composition à libération prolongée contenant de la quétiapine
WO2010100623A1 (fr) 2009-03-04 2010-09-10 Ranbaxy Laboratories Limited Procede de preparation de fumarate de quetiapine
EP2233130A1 (fr) 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited Composition orale à libération prolongée d'un agent antipsychotique
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
US8252801B1 (en) 2009-06-03 2012-08-28 Abbott Laboratories Treatment of schizophrenia and related disorders
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
EP3476218A1 (fr) * 2010-03-11 2019-05-01 Kempharm, Inc. Conjugués d'acides gras de la quétiapine, leur procédé de fabrication et d'utilisation
US8778960B2 (en) 2010-08-23 2014-07-15 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
TR201008261A1 (tr) 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Kontrollü salım gerçekleştiren ketiapin formülasyonları
US8741888B2 (en) 2010-11-09 2014-06-03 Carl A. Forest Sleep aid composition and method
EP3034079B1 (fr) 2010-11-15 2018-01-10 Agenebio, Inc. Dérivés de pyridazine, compositions et méthodes de traitement d'une déficience cognitive
TR201104977A1 (tr) 2011-05-23 2012-12-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım gerçekleştiren kaplamaya sahip ketiapin formülasyonu.
WO2013074048A2 (fr) 2011-08-08 2013-05-23 Mahmut Bilgic Formes pharmaceutiques de type comprimés comprenant un fumarate de quétiapine
CN102391208A (zh) * 2011-10-25 2012-03-28 湖南洞庭药业股份有限公司 富马酸喹硫平的新晶形i及其制备方法
WO2013095312A1 (fr) 2011-12-19 2013-06-27 Mahmut Bilgic Formulations comprenant du fumarate de quétiapine
WO2013100879A1 (fr) 2011-12-27 2013-07-04 Mahmut Bilgic Compositions pharmaceutiques contenant de la quétiapine
WO2013130422A1 (fr) 2012-02-27 2013-09-06 Biovista, Inc. Compositions et méthodes de traitement de maladies mitochondriales
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP2848244A1 (fr) 2013-09-16 2015-03-18 Yildiz Özsoy Erginer Formulations de comprimé à libération prolongée de la quétiapine
EP3083569B1 (fr) 2013-12-20 2022-01-26 Agenebio, Inc. Dérivés de benzodiazépine, compositions et procédés de traitement de la déficience cognitive
CN104016945B (zh) * 2014-05-27 2016-06-29 渭南畅通药化科技有限公司 一种半富马酸喹硫平的制备方法
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11414425B2 (en) 2018-06-19 2022-08-16 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2020025579A1 (fr) 2018-07-31 2020-02-06 Medichem, S.A. Forme posologique solide de fumarate de quétiapine
EP4213817A1 (fr) 2020-09-21 2023-07-26 Sun Pharmaceutical Industries Limited Composition pharmaceutique multiparticulaire de quétiapine
CN113698363A (zh) * 2021-09-15 2021-11-26 苏州敬业医药化工有限公司 一种11-哌嗪-二苯并[b,f][1,4]硫氮杂卓盐酸盐的纯化方法
WO2024039886A1 (fr) 2022-08-19 2024-02-22 Agenebio, Inc. Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive
WO2025172499A1 (fr) 2024-02-15 2025-08-21 Itf Research Pharma, S.L.U Formulations liquides de quétiapine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3389139A (en) * 1963-06-14 1968-06-18 Wander Ag Dr A 6-homopiperazino and piperazinomorphanthridines
FR127F (fr) * 1964-03-27
FR90378E (fr) * 1965-03-26 1968-02-14
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3928356A (en) * 1967-10-06 1975-12-23 Fujisawa Pharmaceutical Co 10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof
CH539044A (de) * 1967-10-06 1973-08-31 Gnii Orch Poluproduktov I Kras Verfahren zur Herstellung quaternärer Ammoniumsalze von 1,3-Bis-(aminomethyl)-imidazolidonen
GB1262509A (en) * 1969-06-20 1972-02-02 Science Union & Cie New tricyclic derivatives and process for their preparation
CA918659A (en) * 1969-07-31 1973-01-09 Yoshitomi Pharmaceutical Industries 11-(4-substituted-1-piperazinyl)-dibenzo (b,f) (1,4) thiazepines
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
BE792426A (fr) * 1971-12-09 1973-06-07 Wander Ag Dr A Nouveaux derives de la dibenzo(b,f)(1,4)thiazepine, leur preparation etleur application comme medicaments
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH569730A5 (fr) * 1972-04-04 1975-11-28 Wander Ag Dr A
CH624682A5 (fr) * 1976-11-10 1981-08-14 Sandoz Ag
US4096261A (en) * 1977-02-23 1978-06-20 Abbott Laboratories Dibenzodiazepines
US4097597A (en) * 1977-02-23 1978-06-27 Abbott Laboratories Dibenzo b,e! 1,4!diazepines

Also Published As

Publication number Publication date
ES2019379B3 (es) 1991-06-16
NO871267D0 (no) 1987-03-26
ZM2987A1 (en) 1991-02-28
FI86059B (fi) 1992-03-31
JPS638378A (ja) 1988-01-14
AU593336B2 (en) 1990-02-08
ZA871940B (en) 1987-11-25
GR3001061T3 (en) 1992-03-20
AR242198A1 (es) 1993-03-31
DE10075016I2 (de) 2002-10-10
MW2087A1 (en) 1987-11-11
FI871137A0 (fi) 1987-03-16
US4879288A (en) 1989-11-07
DE3765969D1 (en) 1990-12-13
EP0240228A1 (fr) 1987-10-07
AU7045987A (en) 1987-10-01
HU201062B (en) 1990-09-28
NO2001009I1 (no) 2001-06-25
HUT47568A (en) 1989-03-28
KR900001868B1 (ko) 1990-03-26
FI871137L (fi) 1987-09-28
JPH064606B2 (ja) 1994-01-19
NO871267L (no) 1987-09-28
LU90593I2 (fr) 2000-08-07
IE59864B1 (en) 1994-04-20
BG61365B2 (bg) 1997-06-30
EP0240228B1 (fr) 1990-11-07
IE870700L (en) 1987-09-27
DD259403A5 (de) 1988-08-24
DK174618B1 (da) 2003-07-21
FI86059C (fi) 1992-07-10
CY98045I1 (el) 2010-07-28
ZW5787A1 (en) 1988-11-02
ATE58132T1 (de) 1990-11-15
NO168771C (no) 1992-04-01
DK158587D0 (da) 1987-03-27
DE10075017I1 (de) 2000-09-21
NL980022I2 (nl) 1998-11-02
CY98045I2 (el) 2010-07-28
PT84569B (pt) 1989-11-30
GB8607684D0 (en) 1986-04-30
NZ219788A (en) 1990-02-26
ES2019379T4 (es) 2015-08-12
PH26516A (en) 1992-08-07
NL980022I1 (nl) 1998-10-01
IL81923A (en) 1991-03-10
DK158587A (da) 1987-09-28
NO168771B (no) 1991-12-23
HK85393A (en) 1993-08-27
CA1288428C (fr) 1991-09-03
KR870008879A (ko) 1987-10-21
GB8706949D0 (en) 1987-04-29
PT84569A (en) 1987-04-01
IL81923A0 (en) 1987-10-20

Similar Documents

Publication Publication Date Title
GR3001061T3 (en) Thiazepine compounds
GB2188317B (en) 4-oxo-quinoline compounds
AR245099A1 (es) N-neoalcanamidas de alquilo inferior utiles como repelentes de insectos, composiciones domesticas, detergentes, repelentes y perfumes que las contienen.
GB8610909D0 (en) Compounds
EP0238443A3 (en) Dicyanobenzanthrone compounds
ZA871063B (en) Aminoacyloxymethyl compounds
GB8630113D0 (en) Compounds
GB8600650D0 (en) Compounds
GB8600262D0 (en) Compounds
GB8600261D0 (en) Compounds
GB8600643D0 (en) Compounds
GB8600644D0 (en) Compounds
GB8600977D0 (en) Compounds
GB8630637D0 (en) Compounds
GB8600648D0 (en) Compounds
GB8629483D0 (en) Compounds
GB8626569D0 (en) Compounds
GB8625187D0 (en) Compounds
GB8622383D0 (en) Compounds
GB8621871D0 (en) Compounds
GB8620952D0 (en) Compounds
GB8615533D0 (en) Compounds
GB8612580D0 (en) Compounds
GB8600612D0 (en) Compounds
GB8611868D0 (en) Compounds